Format

Send to

Choose Destination
Genes Immun. 2011 Sep;12(6):490-4. doi: 10.1038/gene.2011.27. Epub 2011 May 12.

Functional variant ANXA11 R230C: true marker of protection and candidate disease modifier in sarcoidosis.

Author information

1
Laboratory of Immunogenomics and Proteomics, Dept of Immunology, Medical Faculty of Palacky University and University Hospital, Olomouc, Czech Republic. mrazekf@fnol.cz

Abstract

In the recent genome-wide association study the polymorphisms of annexin A11 (ANXA11) gene were associated with susceptibility to sarcoidosis. Beside the replication of this finding and analysis of local ANXA11 expression in bronchoalveolar lavage cells, we wondered whether 'leading' ANXA11 rs1049550 (R230C) variant might also be related to the clinical manifestation of sarcoidosis. The study included 245 Czech patients with sarcoidosis and 254 healthy control subjects. The frequency of ANXA11(*)T allele was significantly lower in patients with sarcoidosis (35%) compared with controls (42%, P=0.04, odds ratio=0.77). Furthermore, ANXA11(*)T allele was less frequent in patients with the infiltration of lung parenchyma by comparison with those with isolated hilar lymphadenopathy (P=0.01). In line with the previous observation, ANXA11 mRNA expression was not deregulated in sarcoidosis and was independent from rs1049550 variant. In conclusion, ANXA11 rs1049550 single nucleotide polymorphism is the susceptibility marker in sarcoidosis, at least in Caucasians. Its role as a disease modifier should be independently replicated.

PMID:
21562576
DOI:
10.1038/gene.2011.27
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center